RecruitingPhase 1NCT06010862

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing Precision Biotech Co., Ltd
Principal Investigator
Fei Li, M.D
The First Affiliated Hospital of Nanchang University
Intervention
CEA CAR-T cells(biological)
Enrollment
36 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Collaborators

The First Affiliated Hospital of Nanchang University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06010862 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials